Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Blood Loss Anemia Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
View directory record Official record
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jul 22, 2026, 10:06 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

NCT04205266
View directory record Official record
Conditions
Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions
Ferumoxytol, Ferrous Sulfate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

NCT01683955
View directory record Official record
Conditions
Acute Blood Loss Anemia, Osteoarthritis, Hip
Interventions
Tranexamic acid, Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Jul 22, 2026, 10:06 PM EDT
Terminated Not applicable Interventional

Role of Blood Management in Perioperative Outcomes

NCT04475497
View directory record Official record
Conditions
Abnormal Uterine Bleeding
Interventions
Blood management, Usual care
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Jul 22, 2026, 10:06 PM EDT
Withdrawn Phase 2 Interventional

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

NCT05509582
View directory record Official record
Conditions
Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Interventions
fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 22, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

NCT04631211
View directory record Official record
Conditions
Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders, Myelodysplastic Syndromes, Platelet Refractoriness
Interventions
Thrombosomes, Liquid Stored Platelets (LSP)
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Duarte, California • Washington D.C., District of Columbia • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding

NCT00395993
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose (FCM), Ferrous Sulfate tablets
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jul 22, 2026, 10:06 PM EDT
Completed No phase listed Observational

IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department

NCT05153278
View directory record Official record
Conditions
Iron Deficiency Anemia Treatment, Iron-deficiency, Iron Deficiency Anemia Due to Blood Loss, Iron Deficiency Anemia
Interventions
Packed red blood cells, Intravenous drug
Biological · Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jul 22, 2026, 10:06 PM EDT
Terminated No phase listed Observational

StatStrip Lactate, Hemoglobin, and Hematocrit Meter in Whole Blood

NCT05118048
View directory record Official record
Conditions
Sepsis, Anemia, Bleeding, Erythrocytosis
Interventions
Lactate, Hemoglobin, Hematocrit
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Timeline
2021
U.S. locations
3
States / cities
Buffalo, New York • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Jul 22, 2026, 10:06 PM EDT
Recruiting No phase listed Observational

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

NCT01257269
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Interventions
Observation
Other
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Results available

Thrombosomes® in Bleeding Thrombocytopenic Patients

NCT03394755
View directory record Official record
Conditions
Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
Interventions
Thrombosomes
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Duarte, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 10:06 PM EDT
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

Frozen Red Blood Cell Transfusions in Trauma Patients

NCT01038557
View directory record Official record
Conditions
Blood Loss, Anemia, Trauma
Interventions
RBC units
Biological
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jul 22, 2026, 10:06 PM EDT
Completed No phase listed Observational

Identification of Early Predictors of Fetomaternal Hemorrhage

NCT01232387
View directory record Official record
Conditions
Fetomaternal Hemorrhage, Neonatal Anemia
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Jul 22, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

NCT01933035
View directory record Official record
Conditions
Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
Interventions
Immune Thrombocytopenics, Hypo-proliferative thrombocytopenics, Control Population
Other
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 22, 2026, 10:06 PM EDT
Withdrawn Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP

NCT04039477
View directory record Official record
Conditions
Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Interventions
KZR-616
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 2 Interventional

Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease

NCT00010387
View directory record Official record
Conditions
Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
Interventions
cyclophosphamide, filgrastim
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Not applicable Interventional Results available

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

NCT00360685
View directory record Official record
Conditions
Mucositis, Graft-versus-host Disease
Interventions
Tac+MTX, TAC + MMF
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

NCT00548860
View directory record Official record
Conditions
Anemia
Interventions
Ferric Carboxymaltose, Standard Medical Care (SMC)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
Female only
Enrollment
2,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jul 22, 2026, 10:06 PM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

NCT04404881
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Bevacizumab (Avastin®)
Drug
Lead sponsor
Hanny Al-Samkari, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

NCT01385189
View directory record Official record
Conditions
Hookworm Infection, Hookworm Disease
Interventions
10 μg Na-GST-1/Alhydrogel, 30 μg Na-GST-1/Alhydrogel, 100 μg Na-GST-1/Alhydrogel, 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg), 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg), 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 2Phase 3 Interventional

Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias

NCT07125508
View directory record Official record
Conditions
Anemia, Small Bowel Bleeding, Angioectasias
Interventions
Tranexamic Acid (TXA) treatment, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 10:06 PM EDT
Completed Phase 4 Interventional

Tranexamic Acid in Revision Total Joint Arthroplasty

NCT02877381
View directory record Official record
Conditions
Revision Total Knee Arthroplasty, Revision Total Hip Arthroplasty, Acute Blood Loss Anemia
Interventions
Revision Total Knee Arthroplasty (TKA), Revision Total Hip Arthroplasty (THA)
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Jul 22, 2026, 10:06 PM EDT